ArticleAmerican journal of translational research2023
Agomelatine enhances the therapeutic effect of venlafaxine on depression and improves the levels of S100B and GFAP.
Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
- L-methionine and the L-type CaFrontiers in neural circuits · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine the efficacy of venlafaxine combined with agomelatine in elderly patients with depression and observe the changes in S-100 calcium binding protein B (S-100B) and glial fibrillary acidic protein (GFAP) before and after treatment.
methodsThe data of 142 elderly patients with depression treated in Affiliated Hospital of Gansu Medical College between January 2020 and January 2022 were retrospectively studied. Among the patients, 62 treated with venlafaxine were assigned to a control group, and 80 treated with agomelatine combined with venlafaxine were assigned to an observation group. In addition, 50 patients with suspected meningitis who were treated in Affiliated Hospital of Gansu Medical College over the same time span were enrolled into a normal group. The two groups of patients were compared in terms of clinical efficacy after treatment and the changes in S100B and GFAP before and after treatment. The diagnostic value of S100B and GFAP in patients with depression was explored. Additionally, the changes in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) score before and after treatment were compared between the two groups, and the adverse drug reaction rate was also compared.
resultsThe patient group showed higher cerebrospinal fluid (CSF) levels of S100B and GFAP than the control group (P < 0.001). The areas under the curve (AUC) of CSF S100B and GFAP for diagnosing depression were 0.833 and 0.925, respectively, and the AUC of the combination of the two was 0.967, which was larger than that of CSF S100B or GFAP alone (P < 0.001). Additionally, the control group showed lower clinical efficacy than the observation group (P < 0.001). After treatment, the observation group exhibited lower CSF levels of S100B and GFAP than the control group (P < 0.001), and demonstrated higher RBANS score than the control group (P < 0.001). The difference in adverse drug reaction rate was not significant between the control group and the observation group (P > 0.05).
conclusionS100B and GFAP can be used as diagnostic indicators of depression. Agomelatine plus venlafaxine are superior to venlafaxine alone in the treatment of depression. The combination can contribute to better S100B and GFAP levels, and take a more obvious role in alleviating disease symptoms, thereby improving the cognitive function and overall well-being of patients.
Indexed as
Identifiers
37692959PMC10492076W4386592997What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.